COPD ⭐
copd · society: GOLD · high-yield
← back to Pulmonary & Critical Care
Summary
GOLD 2026 is the 6th major revision of the global strategy for COPD diagnosis, management, and prevention. Key updates include lowering the threshold for GOLD group E to include even one moderate exacerbation, a new Disease Activity framework, clarified initial vs follow-up pharmacological algorithms, new biologic therapy guidance (dupilumab, mepolizumab), updated RSV/pneumococcal/influenza vaccination, completely revised exacerbation and multimorbidity chapters, and a new chapter on AI and emerging technologies. Diagnosis remains anchored on post-bronchodilator FEV1/FVC < 0.7 with active case-finding (not population screening) endorsed.
Current guideline: GOLD 2026 — Global Strategy for Prevention, Diagnosis and Management of COPD · 
download Anki sub-deck